What is the “rolapitant spirocyclic” patent referring to?
“Rolapitant” is an NK1 (neurokinin-1) receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). Patent discussions that mention “spirocyclic” generally point to a specific chemical scaffold type within the rolapitant molecule or related solid forms/derivatives, often described in patent literature as containing a spirocyclic (spiro-ring) structure.
Which patents cover rolapitant’s spirocyclic structure?
Patents that claim rolapitant typically fall into a few buckets:
- claims over the chemical compound itself (including its specific stereochemistry and ring system)
- claims over specific intermediates or manufacturing routes used to build the spirocyclic core
- claims over formulations (for example, oral solid dosage forms) and solid-state forms (polymorphs, solvates, hydrates, amorphous forms)
To identify the exact “rolapitant spirocyclic” patent, you usually need one of these to narrow to a specific patent document:
- the patent number (or publication number like WO/EP/US)
- the jurisdiction (US, EP, WO, CN, etc.)
- the assignee/company name
- an exact phrase from the claim/specification (for example, how the spirocyclic part is described)
How do I find the exact “rolapitant spirocyclic” patent fastest?
If you have any of the following, you can quickly pinpoint the document in patent databases (Google Patents, Lens.org, Espacenet):
- search for “rolapitant” plus “spirocyclic” (or “spiro” in combination with “NK1”)
- search within claims for terms like “spiro[...], spirocyclic, spiro ring”
- filter by assignee (often the original developer of rolapitant) and by the publication year range around the original compound filings
If you share the jurisdiction (US/WO/EP/etc.) or the company/assignee you saw mentioned, I can help narrow what to search for and how to interpret the claim language you find.
Does the spirocyclic patent matter for generic/biologic competition timing?
For small-molecule NK1 antagonists like rolapitant, the key exclusivity drivers tend to be whichever patents remain in force covering:
- the active ingredient (compound) and/or its specific stereochemistry
- key polymorph/solid-state forms used in the marketed product
- manufacturing process steps (if claimed)
- method-of-use claims (if any)
When those patents expire (and after regulatory data exclusivity/market exclusivity—if applicable in a given country), competitors can generally use alternative manufacturing and formulations, but only if they avoid infringing any still-in-force compound/solid-form/process claims.
What you should provide to identify the specific patent
Send any one of:
- the exact patent/publication number you’re looking at (e.g., WO20xx..., US20xx..., EP....)
- a link to the patent page
- the assignee/company name shown next to it
- the exact wording around “spirocyclic” from the claim or abstract
With that, I can tell you what the patent claims (compound vs solid form vs method/process), what the “spirocyclic” language is doing legally/chemically, and how it typically impacts freedom to operate for rolapitant.
Sources
No sources were provided in the prompt, and I don’t have enough information to cite a specific “rolapitant spirocyclic” patent document accurately.